Allena Financial Statements From 2010 to 2022

ALNA
 Stock
  

USD 0.12  0.01  7.69%   

Allena Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Allena Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Allena Pharmaceuticals financial statements helps investors assess Allena Pharmaceuticals' valuation, profitability, and current liquidity needs.
We have found seventy-two available fundamental signals for Allena Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Make sure you validate all of Allena Pharmaceuticals prevailing market performance against the performance between 2010 and 2022 to make sure the company can sustain itself down the road.
Allena Pharmaceuticals Average Assets are projected to decrease significantly based on the last few years of reporting. The past year's Average Assets were at 37.35 Million. The current year Enterprise Value is expected to grow to about 19.5 M, whereas Net Income Per Employee is forecasted to decline to (2.5 M).
  
Check Allena Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allena main balance sheet or income statement drivers, such as Interest Expense of 1.1 M, Operating Expenses of 43.4 M or Research and Development Expense of 32.1 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.42, Total Assets Per Share of 0.43 or Quick Ratio of 0.96. Allena financial statements analysis is a perfect complement when working with Allena Pharmaceuticals Valuation or Volatility modules. It can also supplement various Allena Pharmaceuticals Technical models . Please continue to the analysis of Allena Pharmaceuticals Correlation against competitors.

Allena Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets41.7 M34.8 M60 M
Decreasing
Slightly volatile
Cash and Equivalents36.6 M30 M55.9 M
Decreasing
Slightly volatile
Investments21 M21.2 M23.1 M
Decreasing
Slightly volatile
Investments Current21 M21.2 M23.1 M
Decreasing
Slightly volatile
Property Plant and Equipment Net1.8 M1.6 M556.7 K
Increasing
Slightly volatile
Trade and Non Trade Payables1.1 MM1.9 M
Decreasing
Stable
Total Liabilities16.7 M15.9 M12.6 M
Increasing
Slightly volatile
Shareholders Equity17.9 M18.9 M(4.6 M)
Increasing
Slightly volatile
Current Assets40.4 M33 M59.4 M
Decreasing
Slightly volatile
Assets Non Current1.4 M1.8 M607.1 K
Increasing
Slightly volatile
Current Liabilities12.8 M15.7 M7.1 M
Increasing
Slightly volatile
Liabilities Non Current215.5 K210 K5.2 M
Decreasing
Very volatile
Total Debt11 M10.4 M8.3 M
Increasing
Slightly volatile
Debt Current11 M10.2 M3.7 M
Increasing
Slightly volatile
Debt Non Current215.5 K210 KM
Increasing
Very volatile
Shareholders Equity USD17.9 M18.9 M(4.6 M)
Increasing
Slightly volatile
Cash and Equivalents USD36.6 M30 M55.9 M
Decreasing
Slightly volatile
Total Debt USD11 M10.4 M8.3 M
Increasing
Slightly volatile
Accounts Payable1.4 MM1.9 M
Decreasing
Stable

Allena Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General and Administrative Expense11.2 M12.7 MM
Increasing
Slightly volatile
Research and Development Expense32.1 M35 M19.7 M
Increasing
Slightly volatile
Operating Expenses43.4 M47.6 M25.7 M
Increasing
Slightly volatile
Interest Expense1.1 M976 K334.4 K
Increasing
Stable
Weighted Average Shares73.3 M68 M17.7 M
Increasing
Slightly volatile
Weighted Average Shares Diluted73.3 M68 M17.7 M
Increasing
Slightly volatile

Allena Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditure(684.6 K)(667 K)(196.4 K)
Decreasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals29.1 M27 M(1.2 M)
Increasing
Slightly volatile
Net Cash Flow from Financing34.5 M41.3 M40.2 M
Decreasing
Slightly volatile
Issuance Repayment of Debt Securities (197.7 K)(192.6 K)1.3 M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares34.5 M41.3 M14.6 M
Increasing
Slightly volatile
Net Cash Flow from Investing(684.6 K)(667 K)(210.7 K)
Increasing
Very volatile
Net Cash Flow or Change in Cash and Cash Equivalents(5.2 M)(5.1 M)16 M
Decreasing
Slightly volatile
Share Based Compensation3.1 M3.7 M1.4 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion589.1 K735 K271.2 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity(2.48)(2.413)(0.5485)
Decreasing
Slightly volatile
Price to Book Value2.912.5932.5967
Increasing
Stable
Debt to Equity Ratio0.910.8420.1631
Increasing
Slightly volatile
Current Ratio2.162.10510.3108
Decreasing
Slightly volatile
Book Value per Share0.30.278(14.4822)
Increasing
Slightly volatile
Tangible Assets Book Value per Share0.530.51130.6943
Decreasing
Slightly volatile
Total Assets Per Share0.430.418928.2079
Decreasing
Slightly volatile
Long Term Debt to Equity0.420.390.1932
Increasing
Slightly volatile
Quick Ratio0.960.93627.7194
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets72.7349.851884.3979
Decreasing
Slightly volatile

Allena Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization66.4 M48.9 M154.2 M
Decreasing
Slightly volatile
Enterprise Value19.5 M19 M125 M
Decreasing
Slightly volatile
Invested Capital(545 K)(531 K)M
Increasing
Very volatile
Average Equity19.7 M20.2 M(13 M)
Increasing
Slightly volatile
Average Assets42.4 M37.3 M55.7 M
Decreasing
Slightly volatile
Invested Capital Average6.6 MM12.4 M
Decreasing
Slightly volatile
Tangible Asset Value41.7 M34.8 M60 M
Decreasing
Slightly volatile
Working Capital17.8 M17.3 M51.5 M
Decreasing
Slightly volatile

Allena Fundamental Market Drivers

Short Percent Of Float8.06%
Forward Price Earnings-0.43
Shares Short Prior Month2.56M
Average Daily Volume Last 10 Day20.38M
Average Daily Volume In Three Month32.08M
Date Short Interest15th of July 2022
Fifty Day Average0.1430
Two Hundred Day Average0.3774

Allena Upcoming Events

Upcoming Quarterly Report8th of March 2022
Next Financial Report10th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Allena Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Allena Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Allena Pharmaceuticals investors use historical funamental indicators, such as Allena Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Allena Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Allena Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Allena Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Allena Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Allena Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. Allena Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Allena Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamentals Comparison Now

   

Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Module

Pair Trading with Allena Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allena Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allena Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Allena Pharmaceuticals

0.54ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
0.51HPQHP Inc Fiscal Year End 22nd of November 2022 PairCorr
The ability to find closely correlated positions to Allena Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allena Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allena Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allena Pharmaceuticals to buy it.
The correlation of Allena Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allena Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allena Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allena Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to the analysis of Allena Pharmaceuticals Correlation against competitors. Note that the Allena Pharmaceuticals information on this page should be used as a complementary analysis to other Allena Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fund Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Allena Stock analysis

When running Allena Pharmaceuticals price analysis, check to measure Allena Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allena Pharmaceuticals is operating at the current time. Most of Allena Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Allena Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allena Pharmaceuticals' price. Additionally, you may evaluate how the addition of Allena Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Is Allena Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allena Pharmaceuticals. If investors know Allena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allena Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
13.1 M
Return On Assets
-0.96
Return On Equity
-2.78
The market value of Allena Pharmaceuticals is measured differently than its book value, which is the value of Allena that is recorded on the company's balance sheet. Investors also form their own opinion of Allena Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Allena Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allena Pharmaceuticals' market value can be influenced by many factors that don't directly affect Allena Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allena Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Allena Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allena Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.